Yvonne Greenstreet, Alnylam CEO (Suzanne Kreiter/The Boston Globe via Getty Images)
February 22, 2024 02:36 PM EST
R&D

Al­ny­lam CEO de­fends changes to cru­cial AT­TR tri­al: 'We re­al­ly are play­ing to win'

Lei Lei Wu

News Reporter

NEW YORK — Al­ny­lam’s sur­prise change to the analy­sis plan for one of this year’s most an­tic­i­pat­ed clin­i­cal tri­al read­outs set off a flur­ry of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times